(Q39660788)

13 September 2017

Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells (English)

1 reference

13 September 2017

0 references

1 reference

1 reference

3

1 reference

13 September 2017

4

Atanasio Pandiella

1 reference

13 September 2017

1

Samuel Seoane

1 reference

13 September 2017

Juan Carlos Montero

2

1 reference

PubMed ID

20811002

13 September 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Journal of the National Cancer Institute

13 September 2017

1 reference

13 September 2017

102

1 reference

13 September 2017

1432-1446

1 reference

13 September 2017

18

1 reference

Oncogenic kinase signalling

13 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

The transcriptional repressor Snail promotes mammary tumor recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Trastuzumab: triumphs and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Targeting Src in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Validation of biomarkers for the study of environmental carcinogens: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

The DNA-damage response in human biology and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

The DNA damage response: ten years after

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

ATM phosphorylates histone H2AX in response to DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Cell death: critical control points

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Caspase-independent cell death: leaving the set without the final cut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Src kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

Coupling of mutated Met variants to DNA repair via Abl and Rad51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

The MET receptor tyrosine kinase in invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ315

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJQ315

1 reference

13 September 2017

1 reference

PubMed ID

20811002